应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
90014 永泰生物-B(临时)
休市中 07-26 16:00:00
0.000
+0.000
--
最高
0.000
最低
0.000
成交量
0.00
今开
0.000
昨收
0.000
日振幅
0.00%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
0.00
换手率
--
流通股本
0.00
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
6家公司创新药上市在望,IPO企业盛诺基首创新药报产
证券时报e公司 · 2021-04-15
6家公司创新药上市在望,IPO企业盛诺基首创新药报产
康弘药业:部分创新药产品进展良好,实控人增持彰显信心
中国基金报 · 2021-04-15
康弘药业:部分创新药产品进展良好,实控人增持彰显信心
欧康维视再揽糖尿病黄斑水肿重磅产品 进一步加强眼科创新药产品布局领先地位
中国财富通 · 2021-04-15
欧康维视再揽糖尿病黄斑水肿重磅产品 进一步加强眼科创新药产品布局领先地位
狙击白马,今天轮到药茅了!
格隆汇 · 2021-04-14
狙击白马,今天轮到药茅了!
探秘龙虎榜 | 创新药+医美概念华东医药(000963.SZ)利好跳空高开涨停 广告+抖音概念省广集团(002400.SZ)创近期新高
智通财经 · 2021-04-14
探秘龙虎榜 | 创新药+医美概念华东医药(000963.SZ)利好跳空高开涨停 广告+抖音概念省广集团(002400.SZ)创近期新高
民族制药企业创新“破圈” 豪森药业加速创新药出海和国际合作
中国经济网 · 2021-04-14
民族制药企业创新“破圈” 豪森药业加速创新药出海和国际合作
先声药业(02096)在2021AACR年会上公布创新药重要布局--TNFR2
智通财经 · 2021-04-14
先声药业(02096)在2021AACR年会上公布创新药重要布局--TNFR2
创新药出海第一惨案:临床大“溃败”,康弘药业连续2天跌停,市值蒸发52亿
氨基君 · 2021-04-14
创新药出海第一惨案:临床大“溃败”,康弘药业连续2天跌停,市值蒸发52亿
月涨幅超20%!医美概念到底是“何方神圣”?如何借道基金布局?
东方财富网 · 2021-04-14
月涨幅超20%!医美概念到底是“何方神圣”?如何借道基金布局?
先声药业(02096.HK)创新药管线产品获中国临床试验批准
AAFN · 2021-04-14
先声药业(02096.HK)创新药管线产品获中国临床试验批准
国家突破性放宽海南医卫市场准入 网售处方药解禁最“吸睛”
朱萍 · 2021-04-14
国家突破性放宽海南医卫市场准入 网售处方药解禁最“吸睛”
相关业务是否具有可持续性?诺泰生物回科创板意见落实函
资本邦 · 2021-04-14
相关业务是否具有可持续性?诺泰生物回科创板意见落实函
诺诚健华牵手暨南大学 开展创新药功效评价等合作
新京报 · 2021-04-13
诺诚健华牵手暨南大学 开展创新药功效评价等合作
首度出海却意外折戟,中国创新药企国际化路在何方?
华尔街见闻 · 2021-04-13
首度出海却意外折戟,中国创新药企国际化路在何方?
亚盛医药(06855.HK)公布五个在研原创新药最新临床前进展
AAFN · 2021-04-13
亚盛医药(06855.HK)公布五个在研原创新药最新临床前进展
以岭药业(002603.SZ)创新药苯胺洛芬注射液Ⅲ期临床试验完成CDE公示
智通财经 · 2021-04-12
以岭药业(002603.SZ)创新药苯胺洛芬注射液Ⅲ期临床试验完成CDE公示
以人工智能技术驱动创新药研发,「望石智慧」完成一亿美元B及B+轮融资
胡静怡 · 2021-04-12
以人工智能技术驱动创新药研发,「望石智慧」完成一亿美元B及B+轮融资
新药进了医保进不了医院 专家探讨打通新药落地最后一公里
澎湃新闻 · 2021-04-09
新药进了医保进不了医院 专家探讨打通新药落地最后一公里
加载更多
公司概况
公司名称:
永泰生物-B(临时)
所属市场:
SEHK
上市日期:
--
主营业务:
公司是中国一家领先的细胞免疫治疗生物医药公司,近年来专注于T细胞免疫治疗药物研发和商业化。根据弗若斯特沙利文报告,公司的核心在研产品EAL是中国首款获准进入II期临床试验的免疫细胞产品,也是截至最后实际可行日期中国唯一获准进入实体瘤治疗II期临床试验的免疫细胞产品。EAL产品属多靶点肿瘤细胞免疫治疗产品,在癌症治疗的临床应用方面积累了超过十年的往绩,并对多种癌症显示了治疗效果。公司于2006年起开展有关EAL的研究,对细胞培养体系和方法进行了改进,并开发出具有独立知识产权的、用于生产EAL细胞的专有技术平台。在其以往的临床申请中,EAL已证明在预防肿瘤复发和维持患者的长期存活方面具有效力,且倘与化疗一并使用,治疗功效证明较单独化疗为佳。公司选择了预防肝癌术后复发作为EAL产品临床试验的临床适应症。2018年中国肝癌的新增病例超过40万,占全球肝癌新增病例的44.9%,且五年生存率仅有12.1%,远低于所有癌症40.5%的五年平均生存率。根据弗若斯特沙利文报告,除手术及介入治疗外,中国目前无可供使用的药物及方法能够预防早期肝癌复发及延长早期肝癌患者无复发生存期及总生存期。因此,公司相信EAL产品在上市后将迎来庞大的市场机遇。
发行价格:
--
{"stockData":{"symbol":"90014","market":"HK","secType":"STK","nameCN":"永泰生物-B(临时)","latestPrice":0,"timestamp":1721980800000,"preClose":0,"halted":8,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"07-26 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"symbolChange":{"newSymbol":"06978","executeDate":"2020-06-29"},"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/90014","defaultTab":"news","newsList":[{"id":"2127009033","title":"6家公司创新药上市在望,IPO企业盛诺基首创新药报产","url":"https://stock-news.laohu8.com/highlight/detail?id=2127009033","media":"证券时报e公司","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127009033?lang=zh_cn&edition=full","pubTime":"2021-04-15 17:23","pubTimestamp":1618478596,"startTime":"0","endTime":"0","summary":"人民金融.创新药数据库监测显示,近期亚盛医药的奥瑞巴替尼片、荣昌生物的纬迪西妥单抗、恒瑞医药的脯氨酸恒格列净片和磷酸瑞格列汀片、百奥泰的巴替非班注射液、瀚森制药的艾美酚胺替诺福 ...","market":"sh","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20210415/c628603421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["06978","90014","159992"],"gpt_icon":0},{"id":"2127067660","title":"康弘药业:部分创新药产品进展良好,实控人增持彰显信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2127067660","media":"中国基金报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127067660?lang=zh_cn&edition=full","pubTime":"2021-04-15 16:23","pubTimestamp":1618474980,"startTime":"0","endTime":"0","summary":"目前抗体板块和基因治疗板块都有创新药产品布局并进展良好。在研产品线丰富 部分创新药产品进展良好资料显示,康弘药业是一家致力于中成药、化学药及生物制品的研发、生产、销售及售后服务的医药集团。公司实控人巨资增持 彰显发展信心受暂停康柏西普PANDA试验事件的影响,康弘药业股价在近期出现了较大幅度的波动。而就在公司对外进行回应后不久,康弘药业实控人也出手,给出增持计划。","market":"hk","thumbnail":"https://static.tigerbbs.com/98e661d079a394a2795b91495bc103d7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/98e661d079a394a2795b91495bc103d7"],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2655368900&idx=4&sn=8e65a893de51134d34d036063234b2b4&chksm=8ba15cfbbcd6d5ed4dfb678fc0aabfa54ca71ab185fd655c7eb75eff2ed594c595edd706fa81&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2655368900&idx=4&sn=8e65a893de51134d34d036063234b2b4&chksm=8ba15cfbbcd6d5ed4dfb678fc0aabfa54ca71ab185fd655c7eb75eff2ed594c595edd706fa81&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002773","06978","159992","90014"],"gpt_icon":0},{"id":"2127058040","title":"欧康维视再揽糖尿病黄斑水肿重磅产品 进一步加强眼科创新药产品布局领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2127058040","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127058040?lang=zh_cn&edition=full","pubTime":"2021-04-15 15:28","pubTimestamp":1618471710,"startTime":"0","endTime":"0","summary":"也就是说这1000万美元是欧康维视到产品获批为止所需支付的全部费用。同时Alimera正在进行和一线抗VEGF治疗药物阿柏西普进行上市后的头对头临床。此次欧康维视获取ILUVIEN以后,其在眼底病领域的药物将达到4个,包括即将上市的YUTIQ,和三款治疗黄斑病变的药物。这三款药物横跨了一二线治疗,使欧康维视成为唯一一家实现对黄斑病变治疗全覆盖的公司。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=7D63E%2BxBOrc%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","90014","159992"],"gpt_icon":0},{"id":"2127118021","title":"狙击白马,今天轮到药茅了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2127118021","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127118021?lang=zh_cn&edition=full","pubTime":"2021-04-14 19:31","pubTimestamp":1618399863,"startTime":"0","endTime":"0","summary":"今天上午10点57分,大盘揭晓答案了!","market":"sh","thumbnail":"https://img7.gelonghui.com/apply/11879_20190119/column_article_file_20190119143627711.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/apply/11879_20190119/column_article_file_20190119143627711.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.gelonghui.com/p/460113","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["90014","06978"],"gpt_icon":0},{"id":"2127021756","title":"探秘龙虎榜 | 创新药+医美概念华东医药(000963.SZ)利好跳空高开涨停 广告+抖音概念省广集团(002400.SZ)创近期新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2127021756","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127021756?lang=zh_cn&edition=full","pubTime":"2021-04-14 19:29","pubTimestamp":1618399749,"startTime":"0","endTime":"0","summary":"3,字节跳动概念,华闻集团蹭热点反包一度涨停,中军是省广集团。今日标的选择医美概念华东医药和抖音概念龙头省广集团。华东医药华东医药:龙虎榜阵容强大,深股通对倒净买入4418万元,买二方新侠买入5161万元。公司是药品零售业龙头企业,公司正在全面的往“创新药+医美”两大领域进击。省广集团省广集团:多主力现身龙虎榜,深股通对倒,买卖均衡,买一是知名游资的席位买入4126万元。","market":"hk","thumbnail":"https://static.tigerbbs.com/e0626612eabca994d12e312fb8f69f73","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e0626612eabca994d12e312fb8f69f73"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/449182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000963","06978","90014","DYIN","159992","002400"],"gpt_icon":0},{"id":"2127023514","title":"民族制药企业创新“破圈” 豪森药业加速创新药出海和国际合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2127023514","media":"中国经济网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127023514?lang=zh_cn&edition=full","pubTime":"2021-04-14 16:17","pubTimestamp":1618388257,"startTime":"0","endTime":"0","summary":"近日,江苏豪森药业集团有限公司(以下简称“豪森药业”)与SCYNEXIS(NASDAQ:SCYX)宣布了在大中华地区开发和商业化Ibrexafungerp的战略伙伴关系和许可协议。根据协议,豪森药业将负责Ibrexafu ...","market":"sh","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20210414/c628563488.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20210414/c628563488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992","06978","90014","01477"],"gpt_icon":0},{"id":"2127028954","title":"先声药业(02096)在2021AACR年会上公布创新药重要布局--TNFR2","url":"https://stock-news.laohu8.com/highlight/detail?id=2127028954","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127028954?lang=zh_cn&edition=full","pubTime":"2021-04-14 15:48","pubTimestamp":1618386538,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,近日,先声药业的赵晓峰博士团队在2021年AACR会议上发表了三篇摘要,对II型肿瘤坏死因子受体的生物学机制、小鼠动物模型构建、内部TNFR2抗体的筛选与疗效验证做了细致介绍。II型肿瘤坏死因子受体为TNF受体超家族成员,在多类肿瘤中的选择性表达为表面癌基因,具有促进肿瘤细胞增殖的功能。目前先声药业的TNFR2项目处于临床前阶段的深度开发中,成为了其在肿瘤免疫又一重要的布局。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/448556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","159992","90014","06978"],"gpt_icon":0},{"id":"2127042131","title":"创新药出海第一惨案:临床大“溃败”,康弘药业连续2天跌停,市值蒸发52亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2127042131","media":"氨基君","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127042131?lang=zh_cn&edition=full","pubTime":"2021-04-14 11:31","pubTimestamp":1618371060,"startTime":"0","endTime":"0","summary":"康柏西普在国内市场躺着赚钱的日子已经不多。","market":"us","thumbnail":"http://upload.dudong.com/2021/0414/thumb_185_140_1618370838139.jpg","type":0,"news_type":0,"thumbnails":["http://upload.dudong.com/2021/0414/thumb_185_140_1618370838139.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.dudong.com/post/202104/241406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"dudong_highlight","symbols":["002773","06978","159992","90014"],"gpt_icon":0},{"id":"2127025880","title":"月涨幅超20%!医美概念到底是“何方神圣”?如何借道基金布局?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127025880","media":"东方财富网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127025880?lang=zh_cn&edition=full","pubTime":"2021-04-14 11:00","pubTimestamp":1618369200,"startTime":"0","endTime":"0","summary":"如何借道基金布局?板块从3月11日的低点至今已上涨超20%,4月以来几乎天天在涨。目前来看,没有投资医美板块超过净值比例10%的基金。二胎概念股金发拉比近期也因公告称打造“母婴产品+医疗、医美服务”的新业务模式收,获了6个涨停板。从业绩来看, 爱美客、昊海生科、华熙生物被称为A股市场的“医美三剑客”。对于后市,私募排排网研究主管刘有华表示,医美概念的市场需求是巨大的,特别是人民幸福指数大幅提升之后。","market":"us","thumbnail":"https://static.tigerbbs.com/e0626612eabca994d12e312fb8f69f73","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e0626612eabca994d12e312fb8f69f73"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2021-04-14/doc-ikmyaawa9589711.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2021-04-14/doc-ikmyaawa9589711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["06978","09939","90014"],"gpt_icon":0},{"id":"2127049976","title":"先声药业(02096.HK)创新药管线产品获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2127049976","media":"AAFN","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127049976?lang=zh_cn&edition=full","pubTime":"2021-04-14 08:21","pubTimestamp":1618359672,"startTime":"0","endTime":"0","summary":"先声药业 公布,於4月12日公司的创新药管线产品SIM-307已获得中国国家药品监督管理局签发的药物临床试验批准通知书。SIM-307是基於诺贝尔奖成果水通道学说开发出的一种水通道蛋白4(AQP4)抑制剂,作为脑水肿领域全新作用机制的小分子first-in-class(首创)新药,通过静脉给药方式,拟用於治疗急性重症缺血性卒中并发脑水肿。(sw/t)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1091156&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["06978","03347","159992","90014","02096"],"gpt_icon":0},{"id":"2127046480","title":"国家突破性放宽海南医卫市场准入 网售处方药解禁最“吸睛”","url":"https://stock-news.laohu8.com/highlight/detail?id=2127046480","media":"朱萍","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127046480?lang=zh_cn&edition=full","pubTime":"2021-04-14 05:00","pubTimestamp":1618347600,"startTime":"0","endTime":"0","summary":"建立海南电子处方中心是此次《意见》关注的焦点,也是方便民生的一大红利措施。国家发改委体改司司长徐善长指出,开展互联网处方药销售的措施具有突破性意义。","market":"hk","thumbnail":"https://img.21jingji.com/uploadfile/cover/20210318/202103181259394217_listthumb.jpeg","type":0,"news_type":0,"thumbnails":["https://img.21jingji.com/uploadfile/cover/20210318/202103181259394217_listthumb.jpeg"],"rights":{"source":"21jingji_stock","url":"http://www.21jingji.com/2021/4-14/4OMDEzODFfMTYyNDA4OQ.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;} .Wh span{#sourceStyle#;}.titl{#titleStyle#}a{#lv2TextColor#}","selectors":".content","filters":".colorGreen.detailF, .goindex, .detailShare, .title.T1, ul.Xnew, .sidebar.right","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.21jingji.com/2021/4-14/4OMDEzODFfMTYyNDA4OQ.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"21jingji_stock","symbols":["06978","90014"],"gpt_icon":0},{"id":"2127304253","title":"相关业务是否具有可持续性?诺泰生物回科创板意见落实函","url":"https://stock-news.laohu8.com/highlight/detail?id=2127304253","media":"资本邦","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127304253?lang=zh_cn&edition=full","pubTime":"2021-04-14 00:00","pubTimestamp":1618329600,"startTime":"0","endTime":"0","summary":"4月14日,资本邦了解到,江苏诺泰澳赛诺生物制药股份有限公司(下称“诺泰生物”)回复发行注册环节反馈意见落实函。在回复函中,上交所主要关注公司业务与技术、前五大客户、会计差错更正、产能利用率。","market":"hk","thumbnail":"https://www.chinaipo.com/data/upload/2021/0414/11/60765e0cebf60_300_200.jpg","type":0,"news_type":0,"thumbnails":["https://www.chinaipo.com/data/upload/2021/0414/11/60765e0cebf60_300_200.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.chinaipo.com/news/146738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"chinaipo_stock","symbols":["06978","ONTF","90014"],"gpt_icon":0},{"id":"2127551015","title":"诺诚健华牵手暨南大学 开展创新药功效评价等合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2127551015","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127551015?lang=zh_cn&edition=full","pubTime":"2021-04-13 17:41","pubTimestamp":1618306891,"startTime":"0","endTime":"0","summary":"新京报讯(记者张秀兰)4月13日,港股上市公司诺诚健华宣布,与暨南大学达成共识,在科学研究、人才交流、产业合作等领域展开战略合作,涉及聚焦创新药功效评价等。诺诚健华和暨南大学将开展 ...","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20210413/c628531188.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20210413/c628531188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["90009","159992","90014","06978"],"gpt_icon":0},{"id":"2127181360","title":"首度出海却意外折戟,中国创新药企国际化路在何方?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127181360","media":"华尔街见闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127181360?lang=zh_cn&edition=full","pubTime":"2021-04-13 16:26","pubTimestamp":1618302367,"startTime":"0","endTime":"0","summary":"历时5年,康弘药业当家产品康柏西普眼用注射液海外多中心临床最终告败,这是本土原创生物新药首次尝试国际化,折射中国药企的出海之路或仍是“道阻且长”。\n","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3627458","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3627458","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["159992","06978","90014"],"gpt_icon":0},{"id":"2127099698","title":"亚盛医药(06855.HK)公布五个在研原创新药最新临床前进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2127099698","media":"AAFN","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2127099698?lang=zh_cn&edition=full","pubTime":"2021-04-13 09:02","pubTimestamp":1618275729,"startTime":"0","endTime":"0","summary":"亚盛医药 公布,公司在2021美国癌症研究协会(AACR)年会上展示了五个在研原创新药的七项最新临床前进展,涉及多个癌种,并呈现多种联合用药的潜力。(sw/w)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1090850&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["06855","09939","06978","159938","159992","90014"],"gpt_icon":0},{"id":"2126063512","title":"以岭药业(002603.SZ)创新药苯胺洛芬注射液Ⅲ期临床试验完成CDE公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2126063512","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2126063512?lang=zh_cn&edition=full","pubTime":"2021-04-12 17:49","pubTimestamp":1618220966,"startTime":"0","endTime":"0","summary":"智通财经APP讯,以岭药业(002603.SZ)公告称,近日公司1.1类创新药苯胺洛芬注射液用于治疗术后中、重度疼痛的Ⅲ期临床试验方案完成国家药品监督管理局药品审评中心(CDE)药物临床试验登记与信息公示平台的登记与公示,可以启动Ⅲ期临床试验工作。公告显示,苯胺洛芬注射液由以岭药业与广东中科药物研究有限公司合作开发,发明专利、新药证书和生产批件等项目成果由以岭药业独家拥有。该药属于非甾体类镇痛药,拟用于术后、各种癌痛、外伤、腰痛症(急性期、慢性恶化期)、痛风发作、神经痛、肾及尿结石痛等。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/446871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603","159992","03347","06978","90014"],"gpt_icon":0},{"id":"2126684410","title":"以人工智能技术驱动创新药研发,「望石智慧」完成一亿美元B及B+轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2126684410","media":"胡静怡","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2126684410?lang=zh_cn&edition=full","pubTime":"2021-04-12 17:26","pubTimestamp":1618219606,"startTime":"0","endTime":"0","summary":"“分子设计平台+知识图谱”双引擎","market":"hk","thumbnail":"https://static.tigerbbs.com/d998dfa20b7b0402d1dc07798e3c3efd","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d998dfa20b7b0402d1dc07798e3c3efd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://36kr.com/p/1178548998717696","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"36kr_stock","symbols":["159992","90014","161631","06978"],"gpt_icon":0},{"id":"2126080958","title":"新药进了医保进不了医院 专家探讨打通新药落地最后一公里","url":"https://stock-news.laohu8.com/highlight/detail?id=2126080958","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2126080958?lang=zh_cn&edition=full","pubTime":"2021-04-09 21:12","pubTimestamp":1617973920,"startTime":"0","endTime":"0","summary":" 国家医保局成立以来,目前已组织三次国家医保药品谈判,谈判后的药价以降低50%甚至90%的幅度,让很多患者看到了用上可及创新药的希望。 但是当患者真正走进医院却发现创新药品虽然纳入了医保目录,但是在医院却买不到这些新药。如何打通新药落地最后一公里?4月9日,中国医疗保险研究会召集了多位业内专家畅谈国家谈判创新药落地情况,会上专家究原因、谈看法、提建议。","market":"sh","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxdt/2021-04-09/doc-ikmxzfmk5929004.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2021-04-09/doc-ikmxzfmk5929004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["90014","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是中国一家领先的细胞免疫治疗生物医药公司,近年来专注于T细胞免疫治疗药物研发和商业化。根据弗若斯特沙利文报告,公司的核心在研产品EAL是中国首款获准进入II期临床试验的免疫细胞产品,也是截至最后实际可行日期中国唯一获准进入实体瘤治疗II期临床试验的免疫细胞产品。EAL产品属多靶点肿瘤细胞免疫治疗产品,在癌症治疗的临床应用方面积累了超过十年的往绩,并对多种癌症显示了治疗效果。公司于2006年起开展有关EAL的研究,对细胞培养体系和方法进行了改进,并开发出具有独立知识产权的、用于生产EAL细胞的专有技术平台。在其以往的临床申请中,EAL已证明在预防肿瘤复发和维持患者的长期存活方面具有效力,且倘与化疗一并使用,治疗功效证明较单独化疗为佳。公司选择了预防肝癌术后复发作为EAL产品临床试验的临床适应症。2018年中国肝癌的新增病例超过40万,占全球肝癌新增病例的44.9%,且五年生存率仅有12.1%,远低于所有癌症40.5%的五年平均生存率。根据弗若斯特沙利文报告,除手术及介入治疗外,中国目前无可供使用的药物及方法能够预防早期肝癌复发及延长早期肝癌患者无复发生存期及总生存期。因此,公司相信EAL产品在上市后将迎来庞大的市场机遇。","exchange":"SEHK","name":"永泰生物-B(临时)","nameEN":"Immunotech Biopharm Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(临时)(90014)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(临时)(90014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B(临时),90014,永泰生物-B(临时)股票,永泰生物-B(临时)股票老虎,永泰生物-B(临时)股票老虎国际,永泰生物-B(临时)行情,永泰生物-B(临时)股票行情,永泰生物-B(临时)股价,永泰生物-B(临时)股市,永泰生物-B(临时)股票价格,永泰生物-B(临时)股票交易,永泰生物-B(临时)股票购买,永泰生物-B(临时)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(临时)(90014)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(临时)(90014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}